Abstract:Alzheimer's disease (AD) is the most common form of neurodegenerative disease and disability in the elderly; it is estimated to account for 60%-70% of all cases of dementia worldwide. The most relevant mechanistic hypothesis to explain AD symptoms is neurotoxicity induced by aggregated amyloid-β peptide (Aβ) and misfolded tau protein. These molecular entities are seemingly insufficient to explain AD as a multifactorial disease characterized by synaptic dysfunction, cognitive decline, psychotic symptoms, chronic inflammatory environment within the central nervous system (CNS), activated microglial cells, and dysfunctional gut microbiota. The discovery that AD is a neuroinflammatory disease linked to innate immunity phenomena started in the early nineties by several authors, including the ICC´s group that described, in 2004, the role IL-6 in AD-type phosphorylation of tau protein in deregulating the cdk5/p35 pathway. The "Theory of Neuroimmunomodulation", published in 2008, proposed the onset and progression of degenerative diseases as a multi-component "damage signals" phenomena, suggesting the feasibility of "multitarget" therapies in AD. This theory explains in detail the cascade of molecular events stemming from microglial disorder through the overactivation of the Cdk5/p35 pathway. All these knowledge have led to the rational search for inflammatory druggable targets against AD. The accumulated evidence on increased levels of inflammatory markers in the cerebrospinal fluid (CSF) of AD patients, along with reports describing CNS alterations caused by senescent immune cells in neuro-degenerative diseases, set out a conceptual framework in which the neuroinflammation hypothesis is being challenged from different angles towards developing new therapies against AD. The current evidence points to controversial findings in the search for therapeutic candidates to treat neuroinflammation in AD. In this article, we discuss a neuroimmune-modulatory perspective for pharmacological exploration of molecular targets against AD, as well as potential deleterious effects of modifying neuroinflammation in the brain parenchyma. We specifically focus on the role of B and T cells, immuno-senescence, the brain lymphatic system (BLS), gut-brain axis alterations, and dysfunctional interactions between neurons, microglia and astrocytes. We also outline a rational framework for identifying "druggable" targets for multi-mechanistic small molecules with therapeutic potential against AD.

The immune system on the TRAIL of Alzheimer’s disease

The role of the immune system in Alzheimer's disease

The role of the immune system in Alzheimer’s disease

The Role of TNF Related Apoptosis-Inducing Ligand in Neurodegenerative Diseases.

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Alzheimer's Disease: From Immune Homeostasis to Neuroinflammatory Condition

The signaling and apoptotic effects of TNF-related apoptosis-inducing ligand in HIV-1 associated dementia

Neuroinflammation, Its Role in Alzheimer’s Disease and Therapeutic Strategies

Structural biology of cell surface receptors implicated in Alzheimer’s disease

Therapeutic Targets in Innate Immunity to Tackle Alzheimer's Disease

Emerging Roles of Adaptive Immune Response in Alzheimer's Disease

Immune attack: the role of inflammation in Alzheimer disease

New Insights into Neuroinflammation Involved in Pathogenic Mechanism of Alzheimer's Disease and Its Potential for Therapeutic Intervention

Neuroinflammation in Alzheimer's disease: insights from peripheral immune cells

The immunology of traumatic brain injury: a prime target for Alzheimer’s disease prevention

Neuroinflammation and Neuroimmunology in Alzheimer's disease: The role of T‐lymphocytes in Alzheimer's disease

The neuroimmune axis of Alzheimer's disease

Revisiting the neuroinflammation hypothesis in Alzheimer's disease: a focus on the druggability of current targets

The association of microbial infection and adaptive immune cell activation in Alzheimer's disease

Neuroimmune Mechanisms Underlying Alzheimer's disease: Insights into central and peripheral immune cell crosstalk

The role of innate immunity in Alzheimer's disease